The closing price of VBI Vaccines Inc. (NASDAQ: VBIV) was $0.67 for the day, down -11.18% from the previous closing price of $0.75. In other words, the price has decreased by -$0.0841 from its previous closing price. On the day, 1867080 shares were traded. VBIV stock price reached its highest trading level at $0.7688 during the session, while it also had its lowest trading level at $0.6599.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of VBIV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.65. In the meantime, Its Debt-to-Equity ratio is 2.65 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 11, 2022, Downgraded its rating to Outperform and sets its target price to $2 from $5 previously.
On February 25, 2021, Jefferies started tracking the stock assigning a Buy rating and target price of $7.Jefferies initiated its Buy rating on February 25, 2021, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 10 ’23 when GILLIS STEVEN bought 609,090 shares for $1.65 per share. The transaction valued at 1,004,998 led to the insider holds 1,043,292 shares of the business.
PERCEPTIVE ADVISORS LLC sold 4,251,563 shares of VBIV for $467,672 on Apr 06 ’23. The 10% Owner now owns 41,440,729 shares after completing the transaction at $0.11 per share. On Apr 05 ’23, another insider, PERCEPTIVE ADVISORS LLC, who serves as the 10% Owner of the company, sold 1,832,563 shares for $0.13 each. As a result, the insider received 238,233 and left with 45,691,816 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VBIV now has a Market Capitalization of 15.83M and an Enterprise Value of 33.09M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.95 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 4.07 whereas that against EBITDA is -0.32.
Stock Price History:
Over the past 52 weeks, VBIV has reached a high of $5.90, while it has fallen to a 52-week low of $0.45. The 50-Day Moving Average of the stock is 0.6158, while the 200-Day Moving Average is calculated to be 0.8874.
Shares Statistics:
VBIV traded an average of 227.39K shares per day over the past three months and 724.26k shares per day over the past ten days. A total of 23.69M shares are outstanding, with a floating share count of 22.28M. Insiders hold about 5.94% of the company’s shares, while institutions hold 12.26% stake in the company. Shares short for VBIV as of Mar 15, 2024 were 302.88k with a Short Ratio of 1.33, compared to 371.69k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.28% and a Short% of Float of 1.39%.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.22, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.17 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$6.59 and -$6.59 for the fiscal current year, implying an average EPS of -$6.59. EPS for the following year is -$0.82, with 1 analysts recommending between -$0.82 and -$0.82.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $5.36M to a low estimate of $5.36M. As of the current estimate, VBI Vaccines Inc.’s year-ago sales were $293k, an estimated increase of 1,729.40% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $6.58M, an increase of 1,256.70% less than the figure of $1,729.40% in the same quarter last year. There is a high estimate of $6.58M for the next quarter, whereas the lowest estimate is $6.58M.
A total of 1 analysts have provided revenue estimates for VBIV’s current fiscal year. The highest revenue estimate was $13.19M, while the lowest revenue estimate was $13.19M, resulting in an average revenue estimate of $13.19M. In the same quarter a year ago, actual revenue was $1.08M, up 1,119.00% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $19.84M in the next fiscal year. The high estimate is $19.84M and the low estimate is $19.84M. The average revenue growth estimate for next year is up 50.40% from the average revenue estimate for this year.
